Events and Presentations Events and Presentations Recent Events Virtual KOL Event to Discuss ASCO 2026 Presentation of SIM0505 Phase 1 Dose Escalation Data in Gynecologic Cancers Jun 2, 2026 at 8:00 AM EDT Listen to webcast Expert discussion with Dr. Manning-Geist View the Virtual KOL Event Slides 2.8 MB Presentations ASCO 2026 Poster — Phase I, Multicenter, first-in-human (FIH) global study of SIM0505, an anti-CDH6 antibody-drug-conjugate (ADC) in patients with advanced solid tumors June 2026 Corporate Presentation ASCO 2025 Poster - A Phase 1 Dose Escalation and Dose Expansion Study for LNCB74, A B7-H4 Targeted Antibody Drug Conjugate, As Monotherapy In Participants With Advanced Solid Tumors NXTC-LNCB74 SITC Poster 2024 NXTC – NC410 Combo CRC SITC Poster 2024 Tools
Events and Presentations Recent Events Virtual KOL Event to Discuss ASCO 2026 Presentation of SIM0505 Phase 1 Dose Escalation Data in Gynecologic Cancers Jun 2, 2026 at 8:00 AM EDT Listen to webcast Expert discussion with Dr. Manning-Geist View the Virtual KOL Event Slides 2.8 MB Presentations ASCO 2026 Poster — Phase I, Multicenter, first-in-human (FIH) global study of SIM0505, an anti-CDH6 antibody-drug-conjugate (ADC) in patients with advanced solid tumors June 2026 Corporate Presentation ASCO 2025 Poster - A Phase 1 Dose Escalation and Dose Expansion Study for LNCB74, A B7-H4 Targeted Antibody Drug Conjugate, As Monotherapy In Participants With Advanced Solid Tumors NXTC-LNCB74 SITC Poster 2024 NXTC – NC410 Combo CRC SITC Poster 2024
Virtual KOL Event to Discuss ASCO 2026 Presentation of SIM0505 Phase 1 Dose Escalation Data in Gynecologic Cancers Jun 2, 2026 at 8:00 AM EDT Listen to webcast Expert discussion with Dr. Manning-Geist View the Virtual KOL Event Slides 2.8 MB
ASCO 2026 Poster — Phase I, Multicenter, first-in-human (FIH) global study of SIM0505, an anti-CDH6 antibody-drug-conjugate (ADC) in patients with advanced solid tumors
ASCO 2025 Poster - A Phase 1 Dose Escalation and Dose Expansion Study for LNCB74, A B7-H4 Targeted Antibody Drug Conjugate, As Monotherapy In Participants With Advanced Solid Tumors
